The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Subscribe To Our Newsletter & Stay Updated
